RecruitingPhase 2NCT07268040
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
A Multicenter, Open-label Phase II Clinical Study of SHR-7787 Combined With Other Antitumor Drugs in Patients With Advanced Solid Tumors
Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Enrollment
400 participants
Start Date
Dec 23, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria6
- Ability to understand and voluntarily agrees to participate by giving written informed consent for the study;
- Patients with histologically or cytologically confirmed unresectable solid tumors;
- At least one measurable lesion was identified per RECIST 1.1;
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
- Adequate organ functions as defined per protocol;
- Minimum life expectancy of 3 months.
Exclusion Criteria12
- Patients with known active central nervous system (CNS) metastases;
- History of other malignancy within the past 5 years, with exceptions defined in the protocol;
- Patients with uncontrolled cancer pain;
- Patients with serious cardiovascular and/or cerebrovascular diseases;
- Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion;
- Patients with Severe infections within 4 weeks prior to the first dose;
- Active pulmonary tuberculosis infection;
- History of immunodeficiency;
- History of autoimmune diseases;
- The adverse events of previous antineoplastic therapy did not recover to CTCAE≤ grade 1;
- Pregnant or nursing women, or planned to become pregnant during the study period;
- Known allergic to any component of investigational drugs.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSHR-7787 Injection
SHR-7787 Injection.
DRUGSHR-1316 Injection
SHR-1316 Injection.
DRUGSHR-4849 Injection
SHR-4849 Injection.
DRUGEtoposide injection
Etoposide Injection.
DRUGCarboplatin injection
Carboplatin Injection.
DRUGCisplatin injection
Cisplatin Injection.
DRUGBP102 Injection
BP102 Injection.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07268040
Related Trials
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
NCT037398273 locations
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
NCT070282811 location
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
NCT066295841 location
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
NCT067377311 location
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
NCT024213802 locations